Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesImpact of Concomitant Immunomodulator Use on Long-Term Outcomes in Patients Receiving Scheduled Maintenance Infliximab
Digestive Diseases and Sciences, 06/22/09
Moss AC et al. - The combination of maintenance infliximab and an immunomodulator produced modest improvements in outcomes beyond maintenance infliximab alone in this cohort.
Alan C. Moss, 06/22/09
| Our study found that combining azathioprine or 6MP with infliximab (combination therapy) produced differences in remission rates that were significant at 1 year, but not 2 or 5 year end-points. Theses results are similar to post-hoc analyses of the maintenance studies of infliximab, adalimumab and certolizumab; patients on combination therapy had similar remission rates to those on monotherapy with an anti-TNF. These populations, and ours, are different to those enrolled in the recent SONIC study. The patients enrolled in SONIC had a shorter duration of disease, and were all immunomodulator-naive. Thus one can speculate that intervention with combination therapy early in the course of Crohn's disease produces better results than using this approach later on. Whether using combination therapy in this population will result in any higher risk for serious infections or lymphoma is currently unknown. |
Related Articles
Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09
Relevance Score: 92%
One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçets disease refractory to standard immunosuppressive drugs
Rheumatology International, 10/30/09
Relevance Score: 90%
Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis
Rheumatology International, 11/02/09
Relevance Score: 88%
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Rheumatology International, 10/27/09
Relevance Score: 88%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 87%
Today in Inflammatory Bowel Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
An analysis of the placebo effect in Crohn's disease over time
Alimentary Pharmacology and Therapeutics, 12/04/09
Polymorphisms of the apoptosis-associated gene DP1L1 (deleted in polyposis 1-like 1) in colon cancer and inflammatory bowel disease
Journal of Cancer Research & Clinical Oncology, 12/04/09
Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease
Alimentary Pharmacology and Therapeutics, 12/03/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Atazanavir-Associated Choledocholithiasis Leading to Acute Hepatitis in an HIV-Infected Adult
Annals of Pharmacotherapy, 12/03/09
Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy
Liver Transplantation, 12/03/09
An evidence-based review of natalizumab therapy in the management of Crohn’s disease
Therapeutics and Clinical Risk Management, 12/01/09
Sponsor
Article Search
Sponsor